Browse studies

Find your next paid study

152 recruiting studies matching your filters

A Randomized, Double-blind, Placebo-controlled Study Evaluating the Impact of Milamend on Quality of Life and Hormonal Health in Women With Self-Reported Symptoms Associated With Polycystic Ovary Syndrome (PCOS)

The rationale for this study is to observe the impact of a consumer-grade commercially available product called Milamend Hormone Balance on quality of life and…

Polycystic Ovarian Syndrome (PCOS)

Estimated

~$10 – $8,750

Mila Mend Inc.NCT07764328

Observational

A Pilot Study for Managing Depressive Symptoms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

The purpose of this research is to evaluate the feasibility and effectiveness of Digital Neurotherapy (DNT) or Capacity Coaching (CC) for managing symptoms of …

Autosomal Dominant Polycystic Kidney Disease

Estimated

~$10 – $6,250

Mayo ClinicNCT07745920

Phase 3

A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 Days to Less Than 18 Years of Age With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

To evaluate the pharmacodynamics and safety of tolvaptan in pediatric subjects with ARPKD

Autosomal Recessive Polycystic Kidney (ARPKD)

Estimated

~$10 – $8,750

Otsuka Pharmaceutical Development & Commercialization, Inc.NCT04782258

Phase 2

Phase II Trial of Enfortumab Vedotin in Recurrent and/or Metastatic Adenoid Cystic Carcinoma

The purpose of this study is to find out whether enfortumab vedotin is an effective and safe treatment for people with adenoid cystic carcinoma (ACC).

Adenoid Cystic Carcinoma

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT06891560

Phase 2

A Phase II, Randomized, Double-Blind, Placebo- Controlled Study of Ensifentrine in Subjects With Non-Cystic Fibrosis Bronchiectasis

This study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) deli…

Non-cystic Fibrosis Bronchiectasis

Estimated

~$10 – $8,750

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USANCT06559150

Observational

Streamlined Treatment of Pulmonary Exacerbations in Pediatrics Randomized Controlled Trial (STOP PEDS RCT)

The STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of …

Cystic Fibrosis

Estimated

~$10 – $6,250

University of Washington, the Collaborative Health Studies Coordinating CenterNCT06654752

Comparison of Continous Glucose Monitor and OGTT as a Screen for Cystic Fibrosis Related Diabetes and Impaired Glucose Tolerance

Cystic Fibrosis (CF) related diabetes (CFRD) is a unique form of diabetes mellitus, different from type 1 diabetes and type 2 diabetes. The diagnosis of CFRD i…

Cystic Fibrosis-related DiabetesCystic Fibrosis

Estimated

~$10 – $750

Medical College of WisconsinNCT06560463

Phase 1

A Sequential, Phase 1a/1b, Double-blind, 2-part Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Rev-56 for Inhalation Compared With Placebo in Healthy Adult Participants and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic Pseudomonas Aeruginosa

This is a Phase 1a/1b study to test the safety, tolerability, microbiological response, and pharmacokinetics of inhaled Rev-56 compared to placebo in adult hea…

Healthy ParticipantsNon-cystic Fibrosis Bronchiectasis

Estimated

~$10 – $8,750

Revagenix, Inc.NCT07709494

Phase 2

Bempedoic Acid Therapy for Polycystic Kidney Disease (BEAT-PKD) Randomized Clinical Trial

Autosomal dominant polycystic kidney disease (ADPKD), the most commonly inherited kidney disease, is characterized by the development of cysts in the kidney th…

ADPKD (Autosomal Dominant Polycystic Kidney Disease)

Estimated

~$10 – $7,500

Kenneth HallowsNCT07282821

Phase 1

A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study Evaluating Safety and Pharmacokinetics of VX-581 in Healthy Subjects

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single dose of VX-581 and multiple ascending doses of VX-581 alone a…

Cystic Fibrosis

Estimated

~$10 – $8,750

Vertex Pharmaceuticals IncorporatedNCT07283770

Phase 1

A Phase 1, Open-label, Randomized, Pilot and Feasibility Trial to Evaluate the Safety and Tolerability of the Achromobacter-targeting Bacteriophage Cocktail, AchromoPhage, Among Persons With Cystic Fibrosis and Chronic Achromobacter Lung Infections: The AchromoPhage Trial

The goal of this clinical trial is to learn if a new treatment called AchromoPhage is safe and well tolerated in adults with cystic fibrosis (CF) who have long…

Cystic Fibrosis (CF)Achromobacter Infection

Estimated

~$10 – $7,500

Ghady HaidarNCT07275905

Observational

Rethinking Early Airway Clearence Therapies

The REACT trial consists of two parallel, randomized studies; the Hypertonic Saline Study and the Dornase Alfa Study. Health outcomes among people with cystic…

Cystic Fibrosis (CF)

Estimated

~$10 – $7,500

Nicole HamblettNCT07696338